The Sponsor is studying an investigational medication called danicamtiv to understand its long-term benefits and risks in patients with symptomatic genetic or familial DCM. This study will examine the durability of treatment effects with continued exposure and evaluate appropriateness of chronic dosing over time.
Participants will:
* Take the investigational medicine, danicamtiv, twice daily throughout the study, which is up to 5 years
* Visit the clinic about 16 times for clinical evaluations and diagnostic tests
